NCT06586593
Neoadjuvant Immunotherapy of Operable Metastatic Melanoma in Real Life (GCC)
Recruiting · Not specified · Centre Hospitalier Universitaire de Besancon · registry updated 2024-09-19
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This study aims to evaluate efficacy and tolerance of real life neoadjuvant immunotherapy in advanced yet operable melanoma. The complete histological response will be assessed.
Inclusion
- Patients with operable metastatic melanoma (stage III or IV of American Joint Committee on Cancer \[AJCC\] Stages CLassification) treated with neoadjuvant immunotherapy (anti-PD1 or anti-PD1 + anti-CTLA-4), even if surgery cancelled due to disease progression or complete response or patient\'s refusal to be operated.
- Efficacy of the neoadjuvant immunotherapy histologically of radiologically assessed
Exclusion
- Uveal melanoma